Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 4. 4-methylumbelliferone (4-MU) treatment attenuates doxorubicin resistance of MCF7-DR cells. (A) DR cells were incubated with 0.5 mM 4-MU or vehicle (veh) for 24 h. HAS2 protein levels were monitored using western blotting. (B) NRF2, AKR1C1, and MDR1 protein levels were monitored following the treatment of DR cells with 4-MU for 24 h. (C) DR cells were incubated with 4-MU for 24 h, and intracellular ROS levels were determined following the incubation with 6-Carboxy-2’,7’-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) and subsequent flow cytometry analysis. (D) Sphere formation was assessed after 3 d of sphere culture. Average diameter of spheres was determined using image processing ToupView software (ToupTek Photonics, Zhejiang, China). Values represent the mean ± SD from five different single cells. ap<0.05 compared with vehicle (veh) treatment. (E) Cell viability was monitored after doxorubicin and 4-MU incubation in DR cells using MTT assay. Values represent the mean ± SD from four sampled wells. ap<0.05 compared with the vehicle group. bp<0.05 compared with doxorubicin only group. In the case of western blot results, similar blots were obtained in at least three experiments.
Biomolecules & Therapeutics 2022;30:368~379
© Biomolecules & Therapeutics